The earnings call highlighted strong commercial execution and pipeline advancements, with significant growth in Fanapt sales and strategic investments in infrastructure. However, the financial performance was marred by a significant net loss and increased operating expenses. Overall, the positives in sales and pipeline progression were balanced by financial challenges.

Company Guidance

During the Q3 2025 earnings call, Vanda Pharmaceuticals provided several key metrics and updates. The company reported total net product sales of $56.3 million, reflecting an 18% year-over-year increase. Fanapt sales grew by 31%, with a 35% rise in prescriptions, while HETLIOZ maintained a stable performance with $18 million in sales despite generic competition. Vanda highlighted its advancing pipeline, including the tradipitant NDA for motion sickness, with an FDA PDUFA target action date of December 30, 2025, and the Bysanti NDA for bipolar I disorder and schizophrenia, with a PDUFA date of February 21, 2026. The company is also preparing to submit a BLA for imsidolimab for generalized pustular psoriasis in Q4 2025. Vanda continues strategic investments in its commercial infrastructure, including expanding the Fanapt sales force to approximately 300 representatives, achieving over 100% increase in activity compared to Q3 2024. Total revenue from Fanapt, HETLIOZ, and PONVORY reached $158.9 million for the first nine months of 2025. The company revised its 2025 guidance, expecting total revenues between $210 million and $230 million, with year-end cash projections adjusted to between $260 million and $290 million.

Strong Commercial Execution

Total net product sales reached $56.3 million, up 18% year-over-year, with a 31% increase in Fanapt sales and 35% growth in prescriptions.

Advancing Pipeline

The tradipitant NDA for motion sickness under FDA review with a PDUFA target action date of December 30, 2025; the Bysanti NDA for bipolar I disorder and schizophrenia under FDA review with a PDUFA target action date of February 21, 2026; and the anticipated Q4 submission of the imsidolimab BLA for generalized pustular psoriasis.

Fanapt Sales Force Expansion

A dedicated sales force of approximately 300 representatives led to a significant increase in activity, with the total number of calls growing by more than 20% compared to Q2 2025 and over 100% compared to Q3 2024.

HETLIOZ Market Leadership

HETLIOZ continues to be the market share leader despite the availability of 3 generic products, demonstrating strong brand loyalty.

Vanda (VNDA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VNDA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 11, 2026	2025 (Q4)	-0.96 / -	-0.08	―	―	―
Oct 29, 2025	2025 (Q3)	-0.43 / -0.38	-0.09	-322.22% (-0.29)	―
Jul 31, 2025	2025 (Q2)	-0.36 / -0.46	-0.08	-475.00% (-0.38)	―
May 07, 2025	2025 (Q1)	-0.57 / -0.50	-0.07	-614.29% (-0.43)	―
Feb 13, 2025	2024 (Q4)	-0.11 / -0.08	-0.04	-100.00% (-0.04)	―
Nov 06, 2024	2024 (Q3)	-0.16 / -0.09	0	―	―
Jul 31, 2024	2024 (Q2)	-0.19 / -0.08	0.03	-366.67% (-0.11)	―
May 08, 2024	2024 (Q1)	0.05 / -0.07	0.06	-216.67% (-0.13)	―
Feb 07, 2024	2023 (Q4)	-0.09 / -0.04	0.12	-133.33% (-0.16)	―
Nov 08, 2023	2023 (Q3)	-0.04 / 0.00	0.06	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VNDA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Oct 29, 2025	$5.41	$4.32	-20.15%
Jul 31, 2025	$4.67	$4.26	-8.78%
May 07, 2025	$4.38	$4.22	-3.65%
Feb 13, 2025	$4.70	$4.42	-5.96%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vanda Pharmaceuticals (VNDA) report earnings?

Vanda Pharmaceuticals (VNDA) is schdueled to report earning on Feb 11, 2026, After Close (Confirmed).

What is Vanda Pharmaceuticals (VNDA) earnings time?

Vanda Pharmaceuticals (VNDA) earnings time is at Feb 11, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VNDA EPS forecast?

VNDA EPS forecast for the fiscal quarter 2025 (Q4) is -0.96.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing